TD Asset Management Inc. decreased its holdings in shares of Mylan N.V. (NASDAQ:MYL) by 10.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 201,652 shares of the company’s stock after selling 24,551 shares during the quarter. TD Asset Management Inc.’s holdings in Mylan were worth $6,326,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Meeder Asset Management Inc. raised its position in Mylan by 76.9% during the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after acquiring an additional 1,475 shares in the last quarter. BT Investment Management Ltd bought a new position in shares of Mylan in the third quarter valued at about $142,000. Global X Management Co. LLC raised its position in shares of Mylan by 59.2% in the second quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after purchasing an additional 1,786 shares during the period. Doliver Capital Advisors LP bought a new position in shares of Mylan in the second quarter valued at about $201,000. Finally, Eagle Global Advisors LLC bought a new position in Mylan during the second quarter worth about $205,000. Institutional investors and hedge funds own 73.86% of the company’s stock.
Shares of Mylan N.V. (NASDAQ MYL) opened at $37.41 on Wednesday. Mylan N.V. has a one year low of $29.39 and a one year high of $45.87. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. The firm has a market cap of $20,084.17, a P/E ratio of 7.97, a PEG ratio of 2.05 and a beta of 1.38.
A number of research firms recently commented on MYL. Citigroup set a $42.00 price target on shares of Mylan and gave the stock a “buy” rating in a research report on Wednesday, October 4th. Zacks Investment Research raised shares of Mylan from a “strong sell” rating to a “hold” rating and set a $43.00 price target on the stock in a research report on Tuesday, October 10th. UBS reaffirmed a “buy” rating and set a $46.00 price target (down from $50.00) on shares of Mylan in a research report on Thursday, August 10th. BidaskClub raised shares of Mylan from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Finally, Instinet reiterated a “buy” rating and set a $37.00 price objective on shares of Mylan in a research note on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $41.49.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.